In January 2014, a class-action lawsuit filed against Novartis Consumer Health over its marketing and pricing of Excedrin Migraine was removed to federal court. The complaint, which was originally filed in December 2013 in California state court, alleges that the company misleadingly represents Excedrin Migraine will treat migraines more effectively, and is therefore more expensive, than Excedrin Extra Strength when both medications actually contain the same amounts of the same ingredients. (Cortina et al v. Novartis Consumer Health, Inc., Case No. 14-cv-00069, S. D. CA.).

Two other class-action lawsuits have been filed against Novartis in the last two months making the same allegations, one in New Jersey and one in New York. (Yingst et al v. Novartis AG, Novartis Corporation, and Novartis Consumer Health, Inc., Case No. 13-cv-07919, D. NJ., and Anthony et al v. Novartis AG, Novartis Corporation, and Novartis Consumer Health, Inc., Case No. 14-cv-00161, E. D. NY.)

For more information about other class-action lawsuits regarding Excedrin Migraine and TINA.org’s coverage of the product, click here.

For more information about other class-action lawsuits regarding the deceptive advertising of migraine medications, click here.

 


The Latest

Filters

Fungus Eliminator

Ad Alert

Fungus Eliminator

Forty-five million Americans are ‘fighting a losing battle’ against toenail fungus. Could this supplement be the solution?


Show More